GlassScriptPhysician profile
Lee Andrew Davis
NPI 1144269978
$2,892.56
in general payments reported to CMS, 2019-2025
20 companies · $339 in 2025
The $339 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $405 · 2020: $136 · 2021: $1,134 · 2022: $557 · 2023: $218 · 2024: $103 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $659.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $1,283.35 | 2021-2025 | Pamira, Acticor 7 Vr-T Dx |
| Abbott Laboratories | $409.70 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $302.75 | 2021-2025 | Verquvo |
| Novartis Pharmaceuticals Corporation | $172.12 | 2019-2023 | Leqvio |
| Janssen Pharmaceuticals, INC | $136.33 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $104.68 | 2021-2024 | Lifevest |
| Boston Scientific Corporation | $92.03 | 2022-2023 | Lux-Dx Insertable Cardiac Monitor |
| Astrazeneca Pharmaceuticals LP | $67.62 | 2019-2021 | |
| Baxter Healthcare | $55.69 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Pfizer INC. | $53.66 | 2021-2025 | |
| Lexicon Pharmaceuticals, INC. | $35.98 | 2023-2024 | Inpefa |
| Philips North America LLC | $31.01 | 2023 | |
| Astellas Pharma US INC | $23.68 | 2020 | |
| Cardiva Medical, INC. | $22.22 | 2025 | Cardiva Vascade 6/7f Vcs |
| Bridgebio Pharma, INC. | $22.03 | 2025 | Attruby |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $17.91 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $17.64 | 2024 | |
| Novo Nordisk INC | $17.53 | 2024 | Wegovy |
| Bardy Diagnostics, INC. | $15.00 | 2022 | |
| Esperion Therapeutics, INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.